Industry Satellite Symposia

The American Society for Radiation Oncology (ASTRO) has reviewed and approved these symposia as appropriate for presentation as an Industry Satellite Symposium. The symposia constitute the content and views of the provider and are not part of the official ASTRO Annual Meeting program.

Saturday, September 26, 2026

6:30 p.m. - 8:00 p.m.: Dinner and Hybrid Symposium

Tumor Board: Integrating Immunotherapy With Definitive and Perioperative Radiation Strategies in Stage I-III NSCLC

Location: Westin Boston Seaport District
Commonwealth A-B
425 Summer Street
Boston, MA 02210

CME Credits: Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward ASTRO congress attendees, including an audience of radiation oncologists (primary), with medical oncologists, thoracic surgeons, APPs, oncology nurses, and pharmacists managing stage I-III NSCLC.

Learning Objectives: Upon completion, learners will be better able to:

• Describe the rationale for combining immunotherapy and radiation in NSCLC.
• Evaluate trial evidence for immunotherapy and targeted therapy with radiation in stages I-III.
• Apply MDT input and EGFR status to treatment decisions.
• Manage irAEs in combined modality.

1. Joe Y. Chang, MD, PhD, MS, FASTRO, The University of Texas MD Anderson Cancer Center
2. Nitin Ohri, MD, MS, Albert Einstein College of Medicine / Montefiore Einstein
3. Hossein Borghaei, DO, MS, Fox Chase Cancer Center

Program Agenda:

This activity is supported through an educational grant from AstraZeneca Pharmaceuticals LP.

Sunday, September 27, 2026

6:30 p.m. - 8:00 p.m.: Dinner and Hybrid Symposium

Cases and Conversations – Evolving Radiation Strategies in HER2-Positive Breast Cancer: Early-Stage Through Metastatic Disease

Location: Westin Boston Seaport District
Harbor Ballroom I
425 Summer Street
Boston, MA 02210

CME Credits: Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward ASTRO congress attendees, including an audience of radiation oncologists, medical and surgical oncologists, advanced practice providers, nurses, and other healthcare professionals managing HER2-positive breast cancer.

Learning Objectives: Upon completion, learners will be better able to:

• Evaluate the safety profile of concurrent and sequential radiation therapy with T-DXd, including strategies to distinguish drug-related ILD from radiation pneumonitis.
• Develop a radiation treatment plan that accounts for the overlapping pulmonary and cardiac toxicity risks of ADC-based systemic therapy in HER2-positive breast cancer.
• Assess the implications of recent and emerging clinical trial data for the role of radiation therapy in early-stage and metastatic HER2-positive breast cancer.
• Apply a multidisciplinary framework to integrate systemic and local therapy for HER2-positive breast cancer with brain metastases.

1. Reshma Jagsi, MD, PhD, FASTRO, Emory University
2. Neil M. Iyengar, MD, Winship Cancer Institute of Emory University
3. Lior Z. Braunstein, MD, Memorial Sloan Kettering Cancer Center

Program Agenda:

This activity is supported through educational grants from AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo, Inc.

Monday, September 28, 2026

6:00 p.m. - 7:00 p.m.: Dinner and Hybrid Program

RPT Dosimetry: Why What Was Inherited from EBRT May Not Be Enough

Location: Westin Boston Seaport District
Grand Ballroom CD
425 Summer Street
Boston, MA 02210

CME Credits: This is a non-CME program.

• Understand the differences between EBRT and RPT in terms of dose delivery mechanism, dose rate and distribution, and biological effect.
• Explore why EBRT toxicity thresholds may not be directly applicable to RPT and evaluate the 23 Gy kidney dose threshold across both modalities.
• Understand the clinical significance of inter-patient dosimetry variability.
• Compare 2D versus 2D/3D hybrid dosimetry and STP versus multi-timepoint approaches, including the associated accuracy, resource, and workflow needs.
• Explore data gaps and standardization needs and discuss how a multidisciplinary approach may advance this real-world clinical practice.

1. Amir Iravani, MD, University of Washington-Fred Hutchinson Cancer Center
2. Harshad Kulkarni, MD, BAMF Health
3. Neil Taunk, MD, MS, University of Pennsylvania

Program Agenda:

This activity is independently supported through an educational grant from Lumara Bio.

Monday, September 28, 2026

Show Me the Data™: Redefining Extensive-Stage SCLC — Emerging Therapies, CNS Considerations, and the Radiation Oncologist’s Evolving Role

Location: Westin Boston Seaport District
Harbor Ballroom II-III
425 Summer Street
Boston, MA 02210

CME Credits: Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience: This educational activity is directed toward radiation oncologists (primary), with medical oncologists, APPs, oncology nurses, and pharmacists managing ES-SCLC.

Learning Objectives: Upon completion, learners will be better able to:

• Evaluate emerging systemic therapies for extensive-stage SCLC across lines of therapy.
• Apply evidence on the intracranial activity of emerging agents to individualize treatment.
• Differentiate and co-manage treatment-related adverse events.

1. Kristin Higgins, MD, Winship Cancer Institute of Emory University
2. Alissa J. Cooper, MD, Dana-Farber Cancer Institute
3. Percy Lee, MD, FASTRO, City of Hope National Medical Center

This activity is independently supported through educational grants from Daiichi Sankyo, Inc. and Merck & Co, Inc.